Skip to main content
Andrew Walsh III, MD, Pulmonology, San Marcos, TX, Metropolitan Methodist Hospital

AndrewLeeWalshIIIMD

Pulmonology San Marcos, TX

Critical Care Medicine, Pleural Disease

Physician

Are you Dr. Walsh?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 28 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Andrew Walsh III, MD is a pulmonologist in San Marcos, Texas. He is currently licensed to practice medicine in Texas and Missouri. He is affiliated with CHRISTUS Santa Rosa Hospital - San Marcos, Metropolitan Methodist Hospital, and Nix Health Care System.

Education & Training

  • St Louis University School of Medicine
    St Louis University School of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1990 - 1993
  • The University of Texas Health Science Center at San Antonio
    The University of Texas Health Science Center at San AntonioClass of 1987, MD

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 1990 - 2025
  • TX State Medical License
    TX State Medical License 1988 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • Top MD Consumers Checkbook

Press Mentions

  • Rheumatology Health Care Providers’ Views and Practices on Obesity and Smoking Cessation Management in Rheumatoid Arthritis
    Rheumatology Health Care Providers’ Views and Practices on Obesity and Smoking Cessation Management in Rheumatoid ArthritisJanuary 31st, 2021
  • Hundreds of Alberta Doctors, 3 Major Health-Care Unions Join Calls for ‘Circuit-Breaker’ Lockdown
    Hundreds of Alberta Doctors, 3 Major Health-Care Unions Join Calls for ‘Circuit-Breaker’ LockdownNovember 12th, 2020
  • British Biotech Receives £1.5M to Develop, License New PAH Treatments
    British Biotech Receives £1.5M to Develop, License New PAH TreatmentsJanuary 22nd, 2016

Hospital Affiliations